Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Rosiglitazone controls to tighten

Controls on the use of rosiglitazone are set to tighten further, following a meeting of UK drug safety regulators.

An outright ban on using the drug in combination with insulin has been recommended by the Pharmacovigilance Expert Advisory Group of the Medicines and Healthcare Products Regulatory Agency.

The use of either glitazone with insulin needs to be monitored closely, it adds.

Current advice says the combination should only be used in "exceptional cases".

But diabetes GPs called for the MHRA to change the drug's licence if it feels such combinations are dangerous.

Dr Brian Karet, diabetes lead for North Bradford PCT, said: ‘It's bizarre when only in March they gave pioglitazone a licence to be used with insulin.

‘I'm not aware of any new data since which would make them change their advice.'

Norfolk GP and chair of the Primary Care Diabetes Society. Dr Martin Hadley-Brown said: ‘We have a few patients taking both and I will carry on prescribing the combination for now while keeping a very careful eye on them.'

A spokesperson for the MHRA said it is likely formal advice will change after a recommendation by working group.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say